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USE OF CHART REVIEW TOOL AND PEER FEEDBACK TO INFLUENCE 
PHYSICIAN PRESCRIBING OF CONTROLLED SUBSTANCES 
BRIAN R. PENTI 
ABSTRACT 
Purpose: Develop and evaluate a chart review tool (CRT) to improve the safety and 
effectiveness of prescribing controlled substances in a primary care setting. 
 
METHODS: A Controlled Substance Review Committee, consisting of volunteer 
primary care physicians and a clinical pharmacist, developed a CRT to assess compliance 
with a primary care clinic’s controlled substance prescribing policy and effectiveness of 
therapy. The CRT was based on existing clinic policies and American Pain 
Society/American Academy of Pain Medicine clinical guidelines for opioid prescribing. 
Every month, committee physicians used the CRT to review medical records of patients 
prescribed controlled substances chronically. The CRT tracked factors from the previous 
6 months, including morphine equivalent dose (MED) prescribed, indication for 
treatment, documentation of treatment effectiveness, the Opioid Risk Tool score (ORT 
score), results from urine drug testing (UDT) and patient violations of the clinic’s 
controlled substance policy. These findings are used to provide the treating physician 
constructive, non-punitive feedback. We also assessed if the use of the CRT resulted in 
change in MED prescribed. 
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RESULTS: Ninety-nine patient charts from 14 different physicians were reviewed over 1 
year.  Eighty-eight of these patients were receiving opioids for chronic pain, with an 
average dose in MED 72.6 mg/day (SD 89).  Twenty-nine percent of charts had 
documentation that the controlled substance was improving the patient’s quality of life or 
decreasing their pain.  Sixty percent of patients had at least one violation of the clinic’s 
controlled substance treatment agreement in the prior 6 months, and half of the violations 
were due to missed appointments with specialists to help manage pain.  Patients were 
more likely to have a violation of controlled substance policy in the past 6 months if they 
were prescribed both a benzodiazepine (BZD) and an opioid (p=0.04), had a documented 
treatment agreement  (p=0.002), or were high risk per ORT score (p=0.001). The mean 
dose of opioids, for the 88 patients who were prescribed opioids, decreased 2.6 mg/day 
MED from time of chart review until the end of study (mean duration 6.3 months), 
compared to a 6.9 mg/day MED increase that occurred from 12 months prior to chart 
review to the time of chart review (p=0.01).   
 
CONCLUSION: Development and implementation of a CRT in an urban primary care 
clinic provided helpful insight on prescribing practices, and has promise to improve 
quality of opioid prescribing.  The most common violation of the clinic policy was 
missed appointments with specialists, and patients prescribed both BZD and an opioid or 
were high risk per ORT were most likely to have violations.  Documentation of 
effectiveness of therapy was lacking. 
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INTRODUCTION 
Background 
 According to the CDC, prescription opioid analgesic medications were 
responsible for 18,893 overdose deaths in the U.S. in 2014.1 Heroin was responsible for 
10,574 overdose deaths1 and an additional 6,524 fatal overdoses resulted from 
prescription benzodiazepines (BZDs).2 Eighty percent of first-time heroin users have 
previously misused prescription drugs, especially opioid pain medications.3  Additionally, 
it has been estimated that abuse of opioid analgesics in the United States result in more 
than $55.7 billion in societal costs each year4, despite clear evidence that opioids are 
effective at treating chronic non-cancer pain.20, 21 The risk of adverse outcomes increases 
with escalating doses of opioids, with patients receiving >100 mg morphine equivalent 
dose (MED) /day having a nine-fold increased risk for  overdose and an annual overdose 
rate of 1.8%.5 The risk of overdose with opioids is also increased by the addition of 
prescription BZDs.6  
To address the growing epidemic of opioid abuse, a number of organizations have 
promulgated guidelines for opioid prescribing, which despite imperfect evidence, is a 
basis for standard of care and include monitoring suggestions such as urine drug testing 
(UDT) and treatment agreements.7,8    However, guidelines alone are ineffective in 
changing physician behaviors.9 Peer review and feedback have been used to increase 
guideline concordant care in other realms,19 and have potential to improve opioid 
prescribing. Studies have shown peer review and feedback can lead to improvements in 
physician practices, specifically when health professionals are not performing well at a 
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specific task, the individual providing the feedback is a colleague or supervisor, and the 
feedback is provided multiple times in a timely manner and the feedback includes clear 
targets in writing.19 
In 2011, a family medicine clinic based at a large, urban academic safety-net 
hospital updated its existing controlled substance prescribing policy, which included a 
controlled substance treatment agreement form and other recommendations from existing 
guidelines.  In 2013, a survey of 11 providers at the clinic suggested concerns for 
patients’ safety when prescribing controlled substances.  Concerns included:  
• Inconsistency in prescribing practices 
• Lack of adherence to controlled substance policy by physicians and by 
patients 
• Unfamiliarity with existing guidelines 
• A lack of time to properly assess patients  
• A lack of empowerment to change opioid prescriptions and treatment 
plans begun by another provider   
• A lack of non-pharmaceutical options to treat pain 
• An electronic medical record system that made it difficult to manage 
patients 
Based on these concerns, in August 2013 the clinic initiated a quality 
improvement (QI) project to improve the safety and effectiveness of prescribing 
controlled substances, including opioids and BZDs, through the use of a chart review tool 
(CRT). This paper describes the development, implementation and evaluation of a QI 
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project that features peer-review chart audit processes to improve controlled substance 
prescribing with a CRT.  While this is not documented in the patient’s chart, this could 
potentially be incorporated into the patient’s chart in the future. We hypothesized that use 
of a CRT would lead to a decrease in the amount of opioid prescribed as it would flag 
potential misuse and give feedback to prescribers on safe practices, which include lower 
opioid doses.  
Literature Review: 
Widespread variation in opioid prescribing has been documented in a number of 
studies, including a study that reported a 10-fold difference in prescribing of opioids 
amongst different US states.22  Another study reported that the top 1% of prescribers for 
opioids in Delaware wrote one in four opioid prescriptions.23  A brief and limited review 
of prescribing practices in our clinic showed similar variation in prescribing practices, 
and in some cases, variation in prescribing by provider differed by a factor of 10 in 
regards to the amount of opioids being prescribed (see figure 2 & 3).  
Wide variation to prescribing of opioids may be in part due to lack of compliance 
with existing guidelines, or partly due to the ineffectiveness of the guidelines.  Both of 
these issues may be contributing to the opioid epidemic, given recent concerns about the 
lack of evidence to support the existing guidelines7 and concerns that existing guidelines 
are difficult to implement in busy clinics.10  Research has shown limited compliance in 
following guideline recommendations, with one recent review of urine drug screens 
showing that only 8% to 30% of physicians who prescribe opioids for chronic pain 
obtained urine drug tests for those patients.14   
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While guidelines appear necessary to improving physician performance, they 
alone are not sufficient to improve this performance and local adaptation of the 
guidelines is needed for meaningful changes in physician’s behaviors.24  Practice 
guidelines have been historically difficult to implement in real-world clinical settings, in 
part because the development of guidelines are a highly centralized process, yet 
application of guidelines is a decentralized process done on a local level.  And the 
research that is used to develop the guidelines comes from highly controlled research 
environments, which may be very different from the real-world settings that clinicians 
often work in.  Research has identified a number of barriers that impede the 
implementation of clinical guidelines in real world clinical setting, which include lack of 
awareness,42, 43 lack of familiarity, lack of agreement,25, 42 lack of outcome expectancy 
(i.e. a physician may not think the guideline will improve outcomes),  clinical inertia,25, 44 
and external barriers, such as time limitations.25  Specific barriers to implementing opioid 
prescribing guidelines have been identified, and they include inadequate time and 
resources, relying on general impressions of risk for opioid misuse rather than using 
validated measures, and viewing opioid monitoring as a “law enforcement” activity.26 
Providing medical education to physicians about clinical guidelines, through 
continuing medical education activities such as medical conferences, have historically 
been used to introduce clinical guidelines and can be done with minimal expenses, but 
most studies indicate they are of limited use in changing physician practices.27, 28  To have 
a meaningful impact on physician practices, interventions introducing clinical guidelines 
should involve real-time feedback to practicing physicians.29, 30  Peer review and 
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feedback, if done correctly, can provide such real-time feedback and can lead to 
improvements in physician practices, specifically when health professionals are not 
performing well at a specific task, the individual providing the feedback is a colleague or 
supervisor, and the feedback is provided multiple times in a timely manner, in writing or 
verbally,  and includes clear targets and an action plan.19 This last part indicates that is it 
not good enough to tell someone that they are doing a good or bad job, but rather what 
they can specifically do to improve their performance. Hence, we decided to implement a 
chart review tool and peer feedback to physicians about patients they are actively treating 
as a way to increase knowledge and compliance with existing guidelines for opioid 
prescribing for chronic non-cancer pain. 
CONCEPTUAL FRAMEWORK: 
The amount of opioid prescribed by a physician is impacted by both physician 
and patient factors.  Factors that may influence the physicians’ prescribing practices 
include prior training, existing policies in the clinic that they practice, presence of 
evidence-based guidelines, a lack of non-pharmaceutical alternatives, a lack of time to 
properly monitor and assess patients, clinical inertia, and potentially external influences 
such as societal norms.  Factors that may influence a patient to seek opioids for chronic 
pain, or higher doses of opioids, include a lack of pain control, addictive behaviors, 
environmental and genetic factors,47 a lack of non-pharmacological alternatives,33, 34, 35 
and untreated behavioral health issues.45, 46   
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Figure 1a: Conceptual Framework: Factors that impact the Dose of Opioid: Use Peer 
Feedback/Chart Audit to increase knowledge of existing guidelines with hope to impact 
physician prescribing practices and decrease amount of opioids prescribed 
 
 
 
 The conceptual framework for our intervention (Figure 1a) involves “Diffusion of 
Innovations theory”, which suggests that the spread and adoption of new health 
behaviors, such as implementing clinical care guidelines, can be maximized by tailoring 
interventions to the individuals in the target population.31   Stages of the adoption process 
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for a new innovation such as a clinical guideline, per the diffusion of innovation theory, 
include knowledge (exposure to the innovation), persuasion (interest in knowing more 
about the innovation), decision (to adopt the innovation or not), implementation, and 
confirmation (Figure 1b).  The speed of adoption is determined by the relative advantage 
of the new innovation, the compatibility, the complexity, the trialability, and the 
observability.  Our chart review tool and peer feedback process will be used to increase 
the use of the clinical guidelines (i.e. the rate of diffusion of innovation) by providing the 
clinicians with a tool that is compatible with the work, that is easy to use (limited 
complexity), and we postulate will have a relative advantage by making the prescribing 
of opioids safer.  The hypothesis related to this framework is that the clinical guidelines, 
which were introduced thru a chart review tool and adopted into practice by our 
physicians, will result in decreased opioid prescribing. 
 
Figure 1b: Five stages in the Decision Innovation Process:   
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Objective:  Develop a chart review tool to assess physician opioid prescribing practices 
and implement a process of peer feedback using the chart review tool. 
  
Hypothesis: Peer feedback through the use of the chart review tool will result in a 
decrease in the change in the amount of opioids prescribed from time of chart review to 
the end of the QI project compared to the change in the amount of opioids prescribed 12 
months prior to chart review to time of chart review. 
 
METHODS 
Study Design:  
This was a clinical QI project, featuring a peer-led chart review, with a goal to 
improve the safety of controlled substance prescribing in a Family Medicine outpatient 
practice affiliated with a safety-net academic hospital.  The project was evaluated by 
examining its impact on a key feature of safe prescribing, the amount of opioid (as 
expressed in MED) prescribed before and after chart review. In addition, process data and 
acceptability were analyzed to inform future implementation.   
Development of the Chart Review Tool (CRT)  
The committee consisted of eight volunteer clinicians and a pharmacist with goals 
to review the existing controlled substance prescribing polices and develop a peer review 
process to assess the effectiveness and safety of controlled substance prescribing, aided 
by a chart review tool (CRT). The committee took 4 months to complete the work 
through email communications and occasional in-person meetings. The CRT focuses on 
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assessing the 6 month period prior to time of chart review and is based on the existing 
controlled substance policy at the clinic and the American Pain Society/American 
Academy of Pain Medicine (APS/AAPM) guidelines.8 Reviewers were trained on how to 
complete the CRT during a departmental meeting and during one-on-one training 
sessions. 
The content of the CRT is shown in Table 1, and includes the indication for 
controlled substance, amount of controlled substance prescribed, evidence of patient 
violation of controlled substance policy, presence of potential side-effects, and evidence 
of effectiveness. (See appendix for the complete tool). Amount of opioid prescribed was 
determined by entering opioid formulations into an online calculator12 to determine the 
MED in mg/day. The CRT included the Opioid Risk Tool (ORT)11 table, which 
calculates the risk for potential aberrant drug use behavior, such as overdose, misusing 
prescribed medications, diverting or selling of prescribed medication, or forging 
prescriptions.11 The ORT score rates a patient as low (score <4), moderate (score between 
4 – 7), or high risk (score >7) for these aberrant behaviors based on certain clinical 
factors, such as age and prior substance abuse issues. For this study, the ORT score was 
determined via available data in the chart review. As the tool was originally validated 
using face-to-face assessments to gather data, 11 the chart review method likely 
underestimates the ORT score.  
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Table 1: Data Retrieved Using Patient Chart Review Tool 
Total amount of opiates prescribed, expressed as morphine equivalent dose (MED) per 
day.  
Indication for opiate prescription 
Risk of aberrant behavior based on the Opioid Risk Tool (ORT)11 
Number of urine drug tests (UDT) in past 6 months 
UDT results  
Number of random controlled substance pill counts in past 6 months 
Patient’s compliance with the existing clinic controlled substance policy 
Results from Massachusetts Prescription Monitoring Program (PMP) 
Referrals to specialists or services, such as physical therapist, pain specialist, 
orthopedist, integrative medicine, rehabilitation medicine for the evaluation and 
treatment of pain 
Whether patient arrived at appointment with specialist pain management referral  
Potential side effects from prescribed treatment 
Emergency room visits or related to indication for opiate use or opioid side effect 
Hospital admissions related to indication for opiate use or opioid side effect 
Evidence of improved functioning or quality of life 
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The CRT allowed the reviewer to provide general recommendations to the 
prescribing primary care physician for monitoring based on risk assessment or concerns 
for possible noncompliance.  Those recommendations for monitoring included advice 
based on existing guidelines,8 such as frequency of urine drug screens or pill counts, or 
closer follow-up if there were concerns about non-compliance with the treatment plan 
(e.g. missing physical therapy appointments). To assess feasibility of implementation, 
reviewers documented time needed to complete the chart review with the CRT.   
Implementation 
This QI project took place from October 2013 to September 2014.  The hospital 
clinical data warehouse, a single searchable database of electronic medical record 
systems throughout the hospital, provided a list of patients (aged 18 or higher) who had 
primary care visits at the clinic and were prescribed a controlled substance (defined as 
opioid analgesic medications, benzodiazepines, or amphetamines) monthly for at least 3 
consecutive months during the 1 year period prior to time of request.  From this list, 
charts were randomly selected for review.  Each month, 2–4 volunteer physicians and 
pharmacists reviewed three charts each, specifically looking at the most recent six-month 
period. 
The completed CRT form was then returned to the patient’s primary care 
physician (PCP) with the intent to provide non-punitive, constructive feedback.  The PCP 
was blinded to the identity of the chart reviewer, but the reviewer was aware of the 
identity of the PCP.  The CRT information was not recorded in the patient’s chart and 
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was not used for any administrative purposes. The completed CRT was destroyed via 
hospital protocol after review by the PCP.  
Evaluation: Process and Outcome 
Data for project evaluation included the data from the completed CRT, which was 
entered in a de-identified database before the CRT was given to the PCP. Other data from 
the electronic health record that was entered into the de-identified database included total 
duration of controlled substance therapy, insurance status, gender, race, distance patient 
lived from the clinic, and race/ethnicity. Distance patient lived from the clinic was 
assessed, using googlemaps to assess distance in miles, due to researchers noting a 
pattern of patients receiving higher doses of opioids tended to live further away from the 
clinic. Researchers recorded the amount of opioid prescribed in MED at three points in 
time, which were at twelve months prior to time of chart review, at time of chart review, 
and at completion of the QI project, which varied from 1–11 months (average 6.3 
months) after chart review.  These data were used to determine if there was a change in 
amount of opioids prescribed after a chart review was completed compared to prior to the 
chart review.  For patients who had the controlled substance discontinued at the end of 
the QI project, a brief assessment of the chart was done to determine the reason for the 
discontinuation.  
After completion of the QI project, our institution’s Institutional Review Board 
granted approval to analyze the de-identified data set. Data were analyzed to describe the 
patient population on opioids using descriptive statistics and to assess if the QI project 
had resulted in differences in the amount of opioids prescribed before and after the chart 
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review process.  SAS version 9.3 (SAS Institute, Cary, NC) was used for all statistical 
analyses.  Comparisons of patients based on amount of opioid prescribed at time of chart 
review and number of violations of clinic policy in the prior 6 months was conducted by 
categorizing patients into three categories: (1) ORT score (low, moderate, or high risk); 
(2) BZD’s prescribed in addition to opioids (yes/no); (3) whether or not there was clear 
documentation of a signed treatment agreement in the chart.  Linear regression models 
were conducted to assess the association of various factors on amount of opioid 
prescribed.    We used general linear models with interval scaled outcomes and for binary 
outcomes logistic models. For the dependent variables that were continuous we used 
ordinary least squared regression with selected interaction effects.  The outcomes 
included total amount of opioid prescribed in morphine equivalents. The covariates 
adjustments in the model included: age, gender, race/ethnicity, insurance status 
(Medicare, Medicaid, private), duration of script, indication, opioid risk score, presence 
of BZD, number of violations, and distance from facility. Selected interactions included:  
opioid risk score with number of violations and initial dose of opioid. We note that the 
interactions were not significant in the models.      
Time required to complete the CRT, the number of clinicians participating in the 
chart reviews process, and the number of physicians who had their charts reviewed were 
recorded.  Feedback from participating physicians, both from those who participated by 
reviewing charts and by those who had their charts reviewed, was obtained by surveys 
sent to the physicians via email after completion of the QI project. These survey’s 
consisted of open-ended questions asking for providers’ feedback on the QI project and 
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whether or not we should continue to use the CRT.  An in-depth analysis of the open-
ended questions was not feasible due to the limited number of responses. 
 
RESULTS 
 Ninety-nine patient charts were reviewed by 9 reviewers. Socio-demographics of 
the patients are shown in Table 2.  Eighty-eight were prescribed an opioid analgesic and 
two died during the study period (one from active cancer and one of unknown causes).  
Of these, 16% were also prescribed a benzodiazepine.  The remaining patients not on 
opioid analgesics were either receiving buprenorphine/naloxone (6%) or a 
benzodiazepine (4%). Of the 86 surviving patients on opioid analgesics, none had active 
cancer as an indication for therapy.  The majority of patients were receiving opioids for 
low back pain (55%), chronic pain syndrome/fibromyalgia (15%), or arthritis (13%).     
Table 2: Characteristics of Patients Prescribed Controlled Substances (n=99)* 
Age, mean (SD) 52.25 (10.9) 
Duration of therapy, months (SD) 60.9 (47.9) 
 N  
Female 55  
Ethnicity / Race  
African-American 56 
Caucasian 31 
Latino 10 
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Asian 
Unknown 
1 
1 
Insurance  
Medicare (including dual eligible Medicare/Medicaid) 50 
Medicaid only 41 
Commercial 9 
Type of controlled substance prescribed  
Opioid only 
Low dose (<50 mg MED)  
Medium Dose (>50 mg and <100 mg MED) 
High Dose (>100 mg) 
88 
55 
13 
20 
Benzodiazepine only 4 
Both Opioid and Benzodiazepine 
Buprenorphine 
17 
6 
Tramadol 2 
 
  
Opioid Doses 
The average dose of opioid at time of review was 72.6 mg MED/day (SD 89) 
(Table 2).  Twenty patients (23%) were receiving >100 mg MED/day.  The average 
duration of opioid therapy was 61 months (SD 47.9).  Caucasian patients received 
statistically significant higher doses of opioids than African Americans and Latino 
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patients [(112 mg/day (SD 111) vs. 57.1 mg (SD 80.6) and 59.1 mg (SD 46), respectively 
(p=0.04)] (Table 3).  High-risk patients, based on ORT score, were prescribed higher 
doses of opioids compared to low-risk and moderate risk patients (114.3 mg/day (SD 89) 
vs. 56.1 (SD 77.8) and 78.3 mg (SD 106.2), respectively, p= 0.035) (Table 5).  Patients 
with documented controlled substance treatment agreements in their charts had higher 
doses of opioids compared to those without treatment agreements documented (91.4 mg 
MED vs. 52 mg MED, p=0.04) (Table 5).  Patients living more than 10 miles from our 
clinic were prescribed significantly more opioids than those who lived 10 mile or less 
from our clinic (107.4 mg MED vs 55 mg MED, p=0.04) (Table 5).  Linear regression 
models indicate that dose of opioid was associated with duration of therapy (p=0.001) 
with the dose increasing 0.6 mg with each additional month of treatment in the 12 months 
prior to the intervention. 
Table 3: Mean dose of opioids by ethnicity/race  (n=88), MED* mg/day (sd) 
 Mean (sd) 
Total (n=88) 
Caucasian (n=25) 
72.6 (89) 
112.0 (111.0) 
African American (n=53) 57.1 (80.6) 
Latino (n=9) 59.1 (46.0) 
Asian (n=1) 96.0 (0.0) 
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Provider Practices and Patterns  
Fifty-one percent (n=50) of patients had documentation of treatment agreements 
in their charts (Table 4).  One patient had documentation of a random pill count.  Less 
than one-third of patient charts documented any clinical improvement with controlled 
substance therapy, although there was wide variation in documentation practices. 
Twenty-three percent of patients had documentation of symptoms consistent with known 
side-effects of the prescribed controlled substance, such as constipation, sexual 
dysfunction, or withdrawal symptoms.  
Table 4: Provider Practices per Charts Reviewed (n=99) 
Percentage of patients with Documented Controlled Substance Treatment 
Agreement in chart 
50.1% 
Percentage of patients with Urine Drug Screens (UDT) in past 6 months 
None 
1 
2 
3 or more 
Percentage of patients with UDT, with abnormal results (n=26) 
Amongst patients with abnormal UDT, patient with: 
• Prescribed drug missing (n=20) 
• Abnormal drug present (n=7) 
 
35.0% 
20.5% 
18.0% 
26.5% 
41% 
 
77% 
27% 
Percentage of patients with a random pill count in past 6 months 1% 
Percentage of charts with provider documentation of decreased pain or 
improved quality of life  
29% 
Percentage of charts with provider documentation of symptoms that can be 
explained by possible side-effects from controlled substance 
23% 
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At least one UDT was ordered in 63% (n=62) of patients in the 6 months prior to 
the chart review, for a total of 128 urine drug screens (Table 4). Of the patients who had a 
urine drug screen, 26 patients (41%) had at least one abnormal result. Twenty patients 
had at least one urine with the prescribed drug missing and 7 patients had abnormal drugs 
present (e.g. cocaine).  
Physician action after a violation of the clinic policy, such as an abnormal UDT, 
varied.  While not directly studied, reviewers noted significant variation in how 
physicians documented violations. For example, some physicians would document the 
violation (e.g. Violation #1) and/or note a change in treatment plan following violation, 
while other physicians would make no comment after a violation occurred.  Of note, 5 
patients who had abnormal UDT prior to the CRT but continued to receive the controlled 
substance had additional abnormal UDT after the CRT which resulted in the PCP 
discontinuing the controlled substance prior to the end of the observation period.  
Although it was not part of the final analysis, early preliminary data suggested 
significant variation in prescribing practices amongst the participating physicians.  A 
preliminary investigation of initial 35 chart reviews from 12 different providers showed 
that 24 (69%) of the charts reviewed were from just three physicians (figure 2), 
suggesting that these three physicians were prescribing controlled substances more 
frequently than the other providers.  These findings were persistent after controlling for 
patient panel size (figure 3). 
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Figure 2 Percent patients receiving opioids per provider in Family Medicine Clinic 
 
 
Figure 3: Percent patients on opioid per provider, controlling for sample size 
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Impact on Opioid Prescribing: 
Over the 12 months prior to the chart review, the mean amount of opioid 
prescribed per day, in MED, increased 6.9 mg. In the period of time after the chart review 
(average 6.3 months), there was a 2.6 mg MED mean decrease in the amount of opioid 
prescribed (p <0.01).  Compared to patients with UDT as expected (n=62, average dose 
64.2 mg MED), patients with an abnormal UDT (n=26, average dose 92.7 mg MED) 
experienced a significantly greater decrease in opioid dose after the chart review (-4.8 mg 
MED vs. -1.7 mg MED, p<0.005).  Both groups had a similar increase in the dose of 
opioids prescribed in the 12 months prior to the chart review (6.7 mg MED vs. 7.3 mg 
MED, p=0.16), during which time the results of the UDTs were available for the PCP for 
review.  Longitudinal analysis did not show significant differences in total amount of 
opioids prescribed between the groups. 
Patient Violations of Controlled Substance Policy 
Amongst patients on opioids, 68% (N=54) had at least one violation of the 
clinic’s controlled substance policy in the 6 months prior to chart review, including 33% 
missing scheduled appointments with specialists to help with pain management and 30% 
with abnormal UDT (Table 6).  Twenty-eight percent of patients had multiple violations.  
High-risk patients, per ORT score, had more violations in the 6 months prior compared to 
medium and low-risk patients (2.2 vs. 1.4 and 0.9, respectively, p=0.001) (Table 5).  
Patients prescribed both an opioid and a benzodiazepine had more violations in the past 6 
months compared to patients prescribed just an opioid (1.9 vs. 1.1, p=0.04) and higher 
ORT scores (5.6 vs. 3.3, p=0.02) (Table 5).  Being prescribed both an opioid and a 
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benzodiazepine was associated with a higher likelihood of having an abnormal UDT (OR 
3.0; p=0.0003). Patients with documented controlled substance treatment agreements also 
had a higher number of violations in the prior 6 months (1.7 vs. 0.8, p=0.002) (Table 5).  
Table 5: Characteristics based on distance patient lives from clinic, presence of 
Treatment Agreement, Opioid Risk Score, and prescribing of Benzodiazepine 
 n (%) Ave MED 
(mg/day) 
Viol past 6 
months 
Opioid Risk Score    
Low  50 (57%) 56.1 (77.8) 0.9 (1.2) 
Moderate  21 (24%) 78.3 (106.2) 1.4 (1.2) 
High  17 (19%) 114.3 (89) 2.2 (1.4) 
Analysis of Variant  P=0.035 p=0.0015 
Distance from clinic in miles    
• Near (<5 miles) 51 (58%) 56.2 (82.6) 1.3 
• Moderate (5–10 miles)  8 (9%) 50.8 (75.3) 1.0 
• Far (>10 miles) 29 (33%) 107.4 (96.3) 1.2 
Analysis of Variant  0.04 0.8 
Treatment Agreement    
• Absent 45 (52%) 52 (80.1) 0.8 (1.1) 
• Present 43 (48%) 91.4 (93.4) 1.7 (1.4) 
Analysis of Variance  P=0.04 P=0.002 
Prescribed BZD & Opioid    
• Yes 16 (18%) 77.5 (100) 1.9 (1.5) 
• No 72 (82%) 71.5 (87.4) 1.1 (1.2) 
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Table 6: Types of Violations in past 6 months 
Percent of patients with Evidence of Violation of controlled 
substance policy in past 6 months 
61%  
Type of Violation    
None 39%  
Missed Appointments with Specialist 33%  
o Integrative Medicine  3% 
o Pain Clinic  8% 
o Orthopedics, Sports Medicine, Physical therapy  11% 
Abnormal Urine Drug Screen 19%  
Missed Multiple PCP appointments 10%  
Getting Opioids from Outside Provider  8%  
Calling After hours for refills 2%  
Seek Early Refills 2%  
Lost Prescription  1%  
Disrespectful to staff 1%  
Increase Dose without PCP approval 1%  
Multiple Violations 28%  
 
When referred to a specialist to help address chronic pain issues, a preliminary 
assessment of the data indicated that patients clearly made it to their appointment in 44% 
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of the cases (Figure 4).  In 36% of the cases, there was clear indication that the patient 
missed the appointment, and in 20% of the cases the data were not available to determine 
if the patient made the appointment or not.  Patients were most likely to miss 
appointments with the pain clinic and with integrative medicine specialist.  The 
information to confirm or deny if patients made their appointments with the physical 
therapist was mostly unavailable.  
 
Figure 4: Attendance to referred Specialist 
 
Physician Involvement: 
Ten physicians and one pharmacist performed the chart reviews, and most 
reviewed 3–6 charts during the year. Fourteen physicians received at least one completed 
CRT.  Average time to complete a single chart review was 13.5 minutes.  
Informal feedback from participating physicians found the process of completing a CRT 
and receiving feedback constructive.  Examples of the feedback received include: 
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• “I read the review forms and found them extremely helpful.  I would like to 
continue to receive feedback.” 
• “This provides objective data on how often things have been done & whether 
things are well documented” 
• “I think everyone should participate (on chart reviews” yearly or biyearly.. I 
think it will improve prescribing practices” 
• “I have greatly benefited from it and would certainly support a standardized 
approach.” 
DISCUSSION 
Developing and implementing a chart review tool (CRT) to assess controlled 
substance prescribing was feasible and showed promise for improving opioid prescribing 
practices. The CRT provided findings that can be used to improve prescribing practices, 
such as data about the types of violations to our controlled substance policy (e.g., missing 
appointments to specialists).   In addition, the CRT provided clinically important 
information about the patient population, including characteristics of patients more likely 
to violate the controlled substance policy, such as those receiving both opioids and BZDs 
and those patients with high ORT scores.  Furthermore, initial findings suggest the chart 
review tool has the potential to impact the total amount of opioids being prescribed, 
particularly among patients with abnormal UDT. 
While it is not clear how representative this sample of physicians and patients is 
compared to other populations, the concerns noted by physicians in our clinic in the 
initial survey done in 2013 were similar to concerns documented by physicians in other 
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studies.  Previous research shown, per the physicians, that the major barriers to safely 
prescribing opioids according to existing guidelines were inadequate time and resources, 
relying on general impressions of risk for opioid misuse, and viewing opioid monitoring 
as a “law enforcement”.26  Our physicians clearly stated concerns about not having 
enough time, and also stated being unfamiliar with existing guidelines, which included 
using validity measures to assess for risk of opioid misuse.   
In addition, our project, using a chart review process to determine ORT scores, 
found similar rates of high-risk patients on opioids (approximately 20%) as previous 
studies.11 Our data showed Caucasian patients receiving higher doses of opioids than 
African American and Hispanic patients, which is consistent with earlier studies.15,16 
Findings in this paper regarding variable use of UDT and treatment agreements and also 
that patients on higher doses of opioids are more likely to have a treatment agreement are 
corroborated by previous research.13, 14   
Of note, more than 50% of the violations of clinic policy were related to patients 
missing appointments to specialty services to help manage their pain, suggesting a need 
for further investigation. Previous studies on treatment agreements have documented that 
the most common reason for violation has been the presence of abnormal UDT and using 
opioids other than those prescribed. 14,17, 18  The rate of non-compliance with specialty 
care which we observed has not been carefully examined among patients on controlled 
substances. This is particularly important given recent recommendations in the federal 
Interagency Pain Research Coordinating Committee’s (IPRCC) National Pain Strategy 
which emphasizes the importance of interdisciplinary treatments in treating chronic 
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pain.32  The IPRCC was developed by the Health and Humans Services agency to 
coordinate all pain research efforts. The documented poor attendance to these referred 
specialty services, such as pain specialists and integrative medicine specialists, by 
patients with chronic pain on controlled substances may warrant special attention given 
the limited availability of these resources in the general population, especially amongst 
under-served populations.33, 34, 35 Additional research should be done to explore ways to 
improve communication and coordination of care between specialist and primary care 
physicians, especially for patients who are prescribed controlled substances because 
missing these appointments may be a violation of their treatment agreement.  More 
importantly, patients may be missing out on important therapeutic interventions that may 
improve their quality of life and decrease their dependency on the prescribed controlled 
substance. 
Variations in opioid prescribing amongst physicians, as noted in our sample, have 
been previously documented.  We chose not to include assessments of individual 
physician prescribing in the final analysis because the study was not designed for this 
purpose, although this may have been helpful in impacting prescribing practices.  
Research has shown providing physicians’ reports about their individual practices 
compared to their peers can be effective in changing physician practices.36   Nonetheless, 
targeting individual outliners may not be enough to curb the current opioid epidemic. 
Based on recent research, the 2013 Medicare claims data for schedule II opioids, shows 
that high-volume prescribers are not solely responsible for the current epidemic of opioid 
overdoses.37 
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Evidence-based effective interventions are needed to improve controlled 
substance prescribing.7,10 Development of an easy to use and effective CRT has the 
potential to improve the safety and effectiveness of controlled substance prescribing.  Our 
CRT process meets the criteria needed to provide effective feedback as noted by the 
Cochrane Review,19 specifically by having colleagues provide written feedback on an 
issue that our clinicians recognize is a problem.  Although recipients of the CRT were not 
formally surveyed, the informal feedback suggests positive receptivity to this method.  In 
addition, the costs for using the CRT were limited to the physician time to complete the 
CRT, which was on average 13.5 minutes per CRT completed. Future versions of the 
CRT could be more focused and less time intensive as we learn which aspects of the CRT 
are most useful to physicians and which aspects can be streamlined.  Given the concerns 
that physicians have stated about a lack of time to assess patients on opioids,26 and data 
suggesting these time constraints are real,38 finding ways to decrease the amount of time 
to complete a CRT should be a priority.  Possible future versions of the CRT process 
could target high risk patients as identified per Opioid Risk Tool, if they receive more 
than 100 mg MED, or receiving both opioid and benzodiazepines. 
Additional risk factors for higher doses of opioids, as identified during our study, 
include living more than ten miles away from the clinic and being on opioids for longer 
periods of time.  It may be that patients who live >10 miles from our clinic were traveling 
there because our clinic is based at tertiary care hospital, but it may also be that their 
previous providers who were closer to them had decided to stop providing them 
controlled substances.  Additional research should be done to clarify why patients who 
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don’t live in the immediate community visit those clinics for controlled substances.  
Additionally, research should be done to explore the impact of duration of opioid therapy 
on patients, as there is appears to be little research on this topic and hence, minimal 
guidance for primary care providers about the optimal duration of therapy. As our study 
has shown, the only factor that appears directly correlated, per regression analysis, with 
the amount of opioid prescribed was duration of therapy, with the amount of opioid 
increasing 0.6 mg MED for every month a patient was prescribed the opioid. 
To develop better interventions to address opioid prescribing, we also will need to 
develop better metrics to assess effectiveness of treating chronic pain.  At presents, there 
is limited evidence for the effectiveness of opioids for chronic non-cancer pain. In a 
systemic review of opioid treatment for chronic back pain,20 the studies assessed were of 
a weak quality and with no significant evidence of benefit with chronic opioid therapy.  
In a Cochrane review of opioids for chronic non-cancer pain, the studies did find 
statistically better pain control with opioids than controls, but the pain relief was modest 
with wide variation in studies that were assessed and with no evidences of improvements 
in functioning or quality of life.21  
Our chart review indicated only 29% of patients had any documentation that 
stated that the medication was helping to decrease pain or improve functioning.  Evidence 
of clinical improvement when treating chronic pain is particularly difficult due to 
research that has shown that the chronic pain intensity, with the passage of time, is less 
associated with nociception but more related to emotional and psychosocial factors.39  
Hence, many of the interdisciplinary treatments recommended per the National Pain 
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Strategy focus on coping strategies with the goal to reduce suffering associated with 
chronic pain rather than strictly focusing on pain scores.32  However, we lack metrics to 
measure coping or suffering that can be used in primary care settings. 
Additionally, more research should be done to explore the potential adverse 
events resulting from prescription opioids used to treat chronic non-cancer pain.  
Research states that the risk of addiction from prescription opioids for chronic pain is 
low, including a Cochrane review that reports only 0.27% of participants in the studies 
reviewed showed signs of opioid addiction,21 yet more than 18,000 people died from 
prescription opioid overdoses in 2014.  These findings seem to be inconsistent with one 
another. Better understanding of the risk from these medications is needed, especially 
when considering research that shows patients believe their physicians should protect 
them from opioid-related harms and are more willing to participate in treatment 
agreements and urine drug testing when discussed as a way to protect them from harm.26 
Future research, using a randomized controlled trial, should be done to assess 
whether or not the chart review tool can be implemented in other settings and whether it 
improves prescribing practices. Previous researchers and clinicians have noted the need 
for developing patient-centered, brief, validated measures of patient-reported safety and 
efficacy.10   Such measures, if developed, would improve the CRT, which is presently 
limited to measuring changes in opioid doses or violations of controlled substance policy 
as the main outcomes. Additionally, clinical practices may wish to explore ways to 
improve communication between primary care physicians and specialists for patients on 
controlled substances, so that clinicians are aware when patients are not receiving 
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prescribed non-pharmacological means to treat their pain (such as physical therapy or 
integrative medicine interventions).  Furthermore, there is unclear guidance about what to 
do when patients exhibit aberrant behaviors or are not clearly improving with controlled 
substance therapy.  Finally, while our study focused on patient violations of the policy, 
we did not assess for individual physician compliance with the policy or individual 
prescribing practices. Future research should explore the role of physicians and 
healthcare systems in potentially unsafe prescribing of controlled substances.   
Limitations to this QI project included a small sample size limited to one clinical 
site, lack of a control group, a quasi-experimental design with threats to the internal 
validity of the findings, such as recent data suggesting a plateau in opioid prescribing40 
and increased public media about the opioid epidemic that have gained their attention, 
and limited time duration of follow-up. Without a control group, causality cannot be 
determined. The small sample size limits the generalizability of this study. Reporting bias 
may exist with physicians reviewing one another, and recording bias may exist with 
incomplete documentation in the medical chart. Another limitation is that patients had 
various intervals from when the chart review occurred and when the project ended, hence 
it is hard to assess if there were significant changes post-intervention given that some 
chart reviews occurred 2 months prior to the end of project, while others had an entire 
year pass between the time of chart review and the end of the project.  Additionally, ORT 
scores were calculated using the CRT, instead of patient self-assessment,11 which likely 
underestimates the true ORT score. 
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Additionally, we could have used additional measures to assess the effectiveness 
of our chart review tool, either process (urine drug screens, treatment agreements, 
random pill counts) or outcomes (dose of opioids, side effects, ED visits, opioids from 
outside providers, abnormal urine drug screens).  Nor did we allow revisions of the chart 
review tool, if we had more time, thru the use of “Plan-Do-Study-Act” change cycles 
typically associated with quality improvement projects.41  
Conclusion 
Providing feedback to physicians on controlled substance prescribing via a CRT 
has the potential to improve the safety of prescribing practices in a busy urban outpatient 
clinic of a safety-net hospital. The chart review tool can offer objective feedback based 
on existing guidelines in a non-punitive manner and may provide meaningful information 
to researchers about opioid prescribing practices.  Further research is needed to assess 
which aspects of the chart review tool are most meaningful and whether these findings 
are generalizable to other clinical settings. 
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APPENDIX 
CONTROLLED SUBSTANCE  REVIEW FORM 
Please: 
• Limit chart review to last 6 months. 
• Please document how time to complete form. 
  
Medical record # 
 
PCP being reviewed (initials): 
 
What controlled substance? (Please circle, & write dose & amount of pills) 
 Dose/amt of tabs 
per month: 
 Dose/amt tabs per mon 
Oxycodone/Percocet  Fentanyl  
Morphine/MS contin  Suboxone  
Ativan/Lorazepam  Methadone  
Klonopin (Clonazepam)  Codeine/Tylenol 3  
Dilaudid (hydromorphone)  Vicodin (hydrocodone)  
Tramadol (ultram)  Flexeril  
Valium (Diazepam)    
Other:_________________________________________ 
 
Indication for controlled substance (i.e. back pain, fibromyalgia, etc.): 
 
Number of PCP Clinic visits in past 6 months.   Does not include phone contact or 
visits to other providers in ACC clinic. 
 
Is there evidence of narcotic contract in the chart? (either narcotic contract printed at 
some point, or other evidence of discussion done?) 
 
In the past 6 months, has the patient had the following done? If so, indicate the 
number of times.  
• Urine toxicology screen:  
o How many:_______ 
o Abnormal drug present?  YES or NO.  If yes, what drug? And how many 
times?  
o Prescribed drug missing?  Yes or No?  If yes, does chart document when 
patient reported last taking med prior to giving urine sample? 
 
• Random Pill Count? 
o How Many? ___________  
o If done, were the results normal or abnormal? 	
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Assess risk of abuse: 
What is the patient’s Opioid Risk Score (based on best of your ability to 
determine)? 
ITEM MARK IF 
PRESENT 
SCORE IF 
FEMALE 
SCORE 
IF MALE 
-Fam hx Sub Abuse 
   -alcohol 
   -illegal drugs 
   -presc drugs 
-NOTHING DOCUMENTED 
 
[  ] 
[  ] 
[  ] 
[  ] 
 
1 
2 
4 
0 
 
3 
3 
4 
0 
-Personal hx of sub Abuse 
   -alcohol 
   -illegal drugs 
   -prescript drugs 
-NOTHING DOCUMENTED 
 
[  ] 
[  ] 
[  ] 
[  ] 
 
3 
4 
5 
0 
 
3 
4 
5 
0 
-Age (<45 yo) [  ] 1 1 
+Hx of sexual abuse 
-NOT Documented 
[  ] 
[  ] 
3 
0 
0 
0 
-Hx Psych dz (ADHD, OCD, Bipolar, 
Schizophrenia) 
-Not Documented 
[  ] 
 
[  ] 
2 
 
0 
2 
 
0 
-Hx Depression 
-not Documented 
[  ] 
[  ] 
1 
0 
1 
0 
TOTAL SCORE    
 LOW RISK 0–3 
MOD RISK 4–7 
HIGH RISK >_8 
   
	
RECEIVING >100 mg Morphine per dayà  Yes or No  
(if yes consider HIGH RISK,  because increase risk of mortality by 9x) 
*** can use online converter:  http://www.globalrph.com/narcoticonv.htm  to calculate 
equivalent dose for different narcotics 
***APS/AAPM Recommends assessment by pain specialist if receiving >100 mg MED 
per day 
 
Based on the risk of abuse, consider potential monitoring strategies: 
LOW RISK: urine tox 1–2x/year, consider random pill count  yearly 
MODERATE RISK: urine tox q 3 months, random pill count 1–2x/year 
HIGH RISK: monthly &/or random urine tox, weekly scripts vs. monthly, 4–6 random 
pill counts/year, referral to pain specialist to review treatment plan  
Has the patient been referred to additional services? If so, is there evidence patient 
made their appointment? 
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 Referral done Made appt Missed appt 
Pain Clinic (Neuro)    
Integrative Medicine Pain Clinic    
Physical Therapy    
Anesthesia for steroid injection    
Sports Medicine    
 
Do you have access to the Mass Online Prescription monitoring program? 
[  ] yes 
[  ] no 
 
If yes, has the patient received multiple prescriptions from different providers in 
past six months? 
[  ] Yes  
[  ] NO 
 
If no, consider enrolling via website: 
http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/drug-control/ma-online-
prescription-monitoring-program/ 
 
 
Is the patient in violation of controlled-substance policy by any of the below items:  
Failing to arrived at scheduled follow-up appointments (either PCP or 
referred specialist) 
YES  NO 
Failure to submit to requested urine testing or pill counts (or abnormal 
results on urine tox or pill count) 
  
Increasing dose of meds without discussing w. PCP   
Seeking early refills   
Calling after hours for refills   
Getting controlled substances from other healthcare providers without 
discussing with PCP 
  
Not treating staff respectfully   
Misrepresenting facts or failing to discuss info to providers   
  
OTHER: 
 
If patient has violated narcotic contract, how many documented violations exist? 
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Is there evidence that the current regimen is helping control pain or improving 
quality of life?      YES OR NO 
Consider using PEG assessment 
• Pain – decreasing pain? 
• Enjoyment- better able to enjoy activities of life? 
• General activity- improved activity levels? 
 
 
Any side effects that could be potentially attributed to the controlled substance?  
Consider problems below that can result from opioid prescribing 
Constipation 
 
Sexual dysfunction Lethargy/somnolence 
Nausea/vomit 
 
Respiratory depression myoclonus 
Pruritis 
 
Urinary retention Withdrawal symptoms 
 
Any admissions or ED visits?  If so, how many and what for?  
 
 
 
Is there a plan in place to stop or decrease dose of controlled substance in future?  
 
SUMMARY: 
Level of Risk based on Opioid Risk Tool:___________________ 
 
Recommended Level of Monitoring:_________________________ 
 
Evidence of Violation of Narcotic Contract?_________________ 
 
Additional Comments: 
 
 
 
 
 
 
 
How much time did it take to complete this form?   
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